Evaluation of the Immune Restoration Potential Of Lenalidomide

Summary

This is phase 2 study of the immunomodulatory drug, lenalidomide, to evaluate potential beneficial effects on the immune system of patients with chronic lymphocytic leukemia (CLL) and CLL-associated immunodeficiency. 17 patients will be enrolled with CLL, small lymphocytic lymphoma (SLL), or monoclonal B-cell lymphocytosis (MBL), and measurable immune compromise, but not an iwCLL indication for CLL therapy (ie non-progressive disease).

Timeline

Start

2017-02-01

Primary completion

2018-12

Completion

2020-12

Outcome

Outcome not reported

Stopped: “withdrawn”

Drugs

Indications